Aberdeen Group plc Buys 243,695 Shares of Oculis Holding AG $OCS

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Aberdeen Group plc grew its stake in shares of Oculis Holding AG (NASDAQ:OCS - Free Report) by 24.1% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,253,119 shares of the company's stock after purchasing an additional 243,695 shares during the quarter. Aberdeen Group plc owned about 2.87% of Oculis worth $23,847,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Bank of America Corp DE increased its position in shares of Oculis by 58.2% during the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock worth $493,000 after purchasing an additional 10,667 shares during the last quarter. Citadel Advisors LLC acquired a new position in shares of Oculis during the 4th quarter worth approximately $389,000. Kestra Private Wealth Services LLC acquired a new position in shares of Oculis during the 1st quarter worth approximately $234,000. Geode Capital Management LLC increased its position in shares of Oculis by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after purchasing an additional 1,800 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Oculis during the 4th quarter worth approximately $225,000. Institutional investors and hedge funds own 22.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Chardan Capital lifted their target price on Oculis from $28.00 to $33.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. HC Wainwright lifted their target price on Oculis from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Friday. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Oculis currently has a consensus rating of "Buy" and an average target price of $35.67.

Oculis Price Performance

OCS traded up $0.05 during trading on Friday, hitting $17.85. The stock had a trading volume of 17,831 shares, compared to its average volume of 11,396. The company has a 50 day moving average price of $18.38 and a 200-day moving average price of $18.68. The firm has a market cap of $779.33 million, a price-to-earnings ratio of -6.69 and a beta of 0.27. Oculis Holding AG has a one year low of $11.56 and a one year high of $23.08.

Oculis (NASDAQ:OCS - Get Free Report) last released its quarterly earnings results on Thursday, August 21st. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.06). The firm had revenue of $0.25 million during the quarter, compared to the consensus estimate of $0.14 million. Oculis had a negative net margin of 13,958.12% and a negative return on equity of 99.12%. As a group, sell-side analysts predict that Oculis Holding AG will post -2.09 EPS for the current fiscal year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.